Genome-wide expression analysis comparing hypertrophic changes in normal and dysferlinopathy mice
Because myostatin normally limits skeletal muscle growth, there are extensive efforts to develop myostatin inhibitors for clinical use. One potential concern is that in muscle degenerative diseases, inducing hypertrophy may increase stress on dystrophic fibers. Our study shows that blocking this pat...
Main Authors: | Yun-Sil Lee, C. Conover Talbot Jr., Se-Jin Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2015-12-01
|
Series: | Genomics Data |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213596015300611 |
Similar Items
-
Développement d’approches thérapeutiques pour le traitement des dysferlinopathies.
by: Pryadkina, Marina
Published: (2014) -
p21-Activated Kinase 1 Is Permissive for the Skeletal Muscle Hypertrophy Induced by Myostatin Inhibition
by: Caroline Barbé, et al.
Published: (2021-06-01) -
Dysferlinopathy: A Case Report and Literature Update
by: Orkide Kutlu, et al.
Published: (2016-12-01) -
High serum myostatin level suggests accelerated muscle senescence in active idiopathic inflammatory myositis
by: Anamika Kumari Anuja, et al.
Published: (2021-01-01) -
Cellular effects of Coenzyme Q10 and resveratrol in the SJL/J dysferlinopathy mouse model
by: Potgieter, Marnie
Published: (2013)